Royalty Pharma to Present at Upcoming Investor Conferences
February 09, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the months of February...
Royalty Pharma To Announce Fourth Quarter And Full Year 2022 Financial Results On February 15, 2023
January 18, 2023 08:25 ET
|
Royalty Pharma plc
NEW YORK, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2022 financial results on Wednesday, February 15,...
Royalty Pharma Highlights Accomplishments and Provides Business Update at 41st Annual J.P. Morgan Healthcare Conference
January 09, 2023 09:25 ET
|
Royalty Pharma plc
2022 Net cash provided by operating activities (GAAP) expected to be approximately $2,140 million to $2,150 million; 2022 Adjusted Cash Receipts(1) (non-GAAP) expected to be approximately $2,785...
Royalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial Readiness
January 09, 2023 09:15 ET
|
Royalty Pharma plc
Royalty Pharma to acquire an interest in SPINRAZA® and pelacarsen royalties – Ionis retains majority of royalties and all milestones from Novartis for pelacarsenRoyalty Pharma to pay Ionis $500...
Royalty Pharma Announces Dividend Increase
January 09, 2023 08:30 ET
|
Royalty Pharma plc
NEW YORK, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2023 of $0.20 per Class A...
Royalty Pharma to Present at the J.P. Morgan Healthcare Conference on January 9
January 04, 2023 16:15 ET
|
Royalty Pharma plc
NEW YORK, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at...
Royalty Pharma Announces Expansion of Senior Leadership Team
December 15, 2022 08:15 ET
|
Royalty Pharma plc
Promotions of Sara Klymkowsky, Brienne Kugler and Alessandra Sassun NEW YORK, Dec. 15, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior...
Royalty Pharma to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 28, 2022 16:26 ET
|
Royalty Pharma plc
NEW YORK, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5th Annual HealthCONx Virtual...
Royalty Pharma Agrees to Acquire Royalty Interest in Olpasiran From Arrowhead for $250 million and Future Milestones
November 09, 2022 08:49 ET
|
Royalty Pharma plc
Olpasiran is an siRNA therapeutic being developed by Amgen to reduce risk of cardiovascular disease Arrowhead retains rights to $400 million in development, regulatory and sales milestone payments...
Royalty Pharma Reports Third Quarter 2022 Results
November 08, 2022 07:00 ET
|
Royalty Pharma plc
Net cash provided by operating activities (GAAP) of $539 million and Adjusted Cash Receipts(1) (non-GAAP) of $597 million Announced transactions of up to $3.0 billion year-to-date, including...